EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment for children with idiopathic pulmonary arterial hypertension Long-term survival and outcomes



Treatment for children with idiopathic pulmonary arterial hypertension Long-term survival and outcomes



Journal of the American College of Cardiology 43(5 Supplement A): 500A, March 3




(PDF emailed within 1 workday: $29.90)

Accession: 035980193

Download citation: RISBibTeXText



Related references

Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. Journal of Heart and Lung Transplantation 24(10): 1626-1631, 2005

Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. American Heart Journal 162(3): 562-568, 2011

Long-term survival in idiopathic pulmonary arterial hypertension associated with massive pulmonary artery dilation. Canadian Respiratory Journal 18(3): E50-E51, 2012

Idiopathic pulmonary arterial hypertension in Asians: a long-term study on clinical outcomes. Chest 147(4): E160-E163, 2015

Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Respirology (): -, 2016

Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. Annals of Thoracic Surgery 94(3): 817-824, 2012

Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sciences 118(2): 414-419, 2015

Long term combination treatment for severe idiopathic pulmonary arterial hypertension. World Journal of Cardiology 2(3): 68-70, 2010

Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics. Clinical Applications 6(5-6): 257-267, 2012

Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 125(1): 113-122, 2012

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122(2): 164-172, 2010

The long-term response to treatment with calcium channel blockers in a patient with idiopathic pulmonary arterial hypertension. Bratislavske Lekarske Listy 114(5): 283-286, 2014

Validation of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survival. Journal of Heart and Lung Transplantation 31(11): 1165-1170, 2013

Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. American Journal of Cardiology 106(9): 1332-1338, 2010

Long-term bosentan treatment in children with pulmonary arterial hypertension. Journal of the American College of Cardiology 47(9): 1914-5; Author Reply 1915, 2006